A1 Refereed original research article in a scientific journal

Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer




AuthorsLaunonen, Inga-Maria; Niemiec, Iga; Hincapié-Otero, María; Erkan, Pekcan Erdogan; Junquera, Ada; Afenteva, Daria; Falco, Matias M.; Liang, Zhihan; Salko, Matilda; Chamchougia, Foteini; Szabo, Angela; Perez-Villatoro, Fernando; Li, Yilin; Micoli, Giulia; Nagaraj, Ashwini; Haltia, Ulla-Maija; Kahelin, Essi; Oikkonen, Jaana; Hynninen, Johanna; Virtanen, Anni; Nirmal, Ajit J.; Vallius, Tuulia; Hautaniemi, Sampsa; Sorger, Peter K.; Vähärautio, Anna; Färkkilä, Anniina

PublisherCell Press

Publication year2024

JournalCancer Cell

Journal name in sourceCancer cell

Journal acronymCancer Cell

Volume42

Issue12

First page 2045

Last page2063.e10

ISSN1535-6108

eISSN1878-3686

DOIhttps://doi.org/10.1016/j.ccell.2024.11.005

Web address https://doi.org/10.1016/j.ccell.2024.11.005

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/477844218


Abstract

Anti-tumor immunity is crucial for high-grade serous ovarian cancer (HGSC) prognosis, yet its adaptation upon standard chemotherapy remains poorly understood. Here, we conduct spatial and molecular characterization of 117 HGSC samples collected before and after chemotherapy. Our single-cell and spatial analyses reveal increasingly versatile immune cell states forming spatiotemporally dynamic microcommunities. We describe Myelonets, networks of interconnected myeloid cells that contribute to CD8+ T cell exhaustion post-chemotherapy and show that M1/M2 polarization at the tumor-stroma interface is associated with CD8+ T cell exhaustion and exclusion, correlating with poor chemoresponse. Single-cell and spatial transcriptomics reveal prominent myeloid-T cell interactions via NECTIN2-TIGIT induced by chemotherapy. Targeting these interactions using a functional patient-derived immuno-oncology platform demonstrates that high NECTIN2-TIGIT signaling in matched tumors predicts responses to immune checkpoint blockade. Our discovery of clinically relevant myeloid-driven spatial T cell exhaustion unlocks immunotherapeutic strategies to unleash CD8+ T cell-mediated anti-tumor immunity in HGSC.


Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Funding information in the publication
This work was supported by the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 667403 for HERCULES and no. 965193 for DECIDER. This study was co-funded by the European Union (ERC, SPACE 101076096 and ERC STRONGER 101125261). Views and opinions expressed are however those of the author(s) only and do not necessarily
reflect those of the European Union or the European Research Council. Neither the European Union nor the granting authority can be held responsible for them. Funding was also received from the Sigrid Juse´ lius Foundation, Research Council of Finland (1339805 and 350396), Cancer Foundation Finland, Finnish Medical, Ida Montini Emil Aaltonen, Biomedicum, K. Albin Johanssons, and Instrumentarium Foundations, Finland, and HORIZON-MSCA-2021- PF, European Commission (M.M.F.: 101067835), Ludwig Cancer Research Center at Harvard Medical School (P.K.S) and R00CA256497 (A.J.N.) from NCI.


Last updated on 2025-27-01 at 19:02